Table 2.

Variables (from 2010) associated with meeting MVPA recommendations on both occasions (n = 389) vs. not meeting MVPA at any occasion (n = 211) (2010 and 2017). A logistic regression model adjusted for age, gender, and smoking habits

2010		na	OR	95% CI	p-value
Age		594	0.979	0.969–0.989	< 0.001
Gender	men	164	1
	women	430	1.176	0.801–1.726	0.407
Smoking habits	Non smoker	251	1
	Smoker	92	0.591	0.357–0.980	0.041
	Previous smoker	251	0.743	0.507–1.089	0.128
Disease duration, years		594	0.996	0.953–1.042	0.875
BMI	18.5–24.9, %	262	1
	< 18.5, %	4	1.050	0.102–10.758	0.968
	25.0–29.9, %	222	0.503	0.334–0.757	0.001
	≥30, %	81	0.242	0.141–0.414	< 0.001
Cardiovasc	no	361	1
	yes	225	0.484	0.330–0.709	< 0.001
Pulmonary	no	545	1
	yes	44	0.483	0.256–0.911	0.025
TJC		587	0.960	0.934–0.987	0.004
SJC		587	0.959	0.927–0.992	0.015
PatGA (0–10)		583	0.883	0.819–0.952	0.001
Pain (0–10)		581	0.908	0.846–0.974	0.007
Fatigue (0–10)		585	0.885	0.830–0.944	< 0.001
HAQ (0–3)		589	0.476	0.344–0.658	< 0.001
EQ 5D (0–1)		578	4.689	2.060–10.677	< 0.001
Tender regions (0–18)		594	0.903	0.862–0.946	< 0.001
DMARD	No DMARD	107	1
	cDMARDb	309	0.886	0.549–1.432	0.622
	Biologicb	153	0.867	0.504–1.494	0.608
	Only CS	18	0.490	0.174–1.383	0.178

^a included in the multivariate analyses, ^bwith and without corticosteroids

BMI Body mass index, TJC Tender joint count, SJC Swollen joint count, PatGA Patient Global Assessment, NRS Numeric rating scale, HAQ Health Assessment Questionnaire, EQ. 5D Euroqol 5 Dimensions, DMARDs Disease modifying anti-rheumatic drugs, cDMARDs Conventional DMARDs, CS Corticosteroids